Purple Biotech Statistics
Total Valuation
Purple Biotech has a market cap or net worth of $10.65 million. The enterprise value is $4.75 million.
| Market Cap | 10.65M |
| Enterprise Value | 4.75M |
Important Dates
The last earnings date was Friday, August 7, 2026, before market open.
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Purple Biotech has 2.17 billion shares outstanding. The number of shares has increased by 267.67% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 2.17B |
| Shares Change (YoY) | +267.67% |
| Shares Change (QoQ) | +16.70% |
| Owned by Insiders (%) | 0.32% |
| Owned by Institutions (%) | 10.83% |
| Float | 3.23B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.87 |
| P/TBV Ratio | 2.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.70, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.70 |
| Quick Ratio | 3.42 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -876.22 |
Financial Efficiency
Return on equity (ROE) is -111.13% and return on invested capital (ROIC) is -22.15%.
| Return on Equity (ROE) | -111.13% |
| Return on Assets (ROA) | -20.31% |
| Return on Invested Capital (ROIC) | -22.15% |
| Return on Capital Employed (ROCE) | -63.68% |
| Weighted Average Cost of Capital (WACC) | 1.41% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.45M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.47% in the last 52 weeks. The beta is -0.53, so Purple Biotech's price volatility has been lower than the market average.
| Beta (5Y) | -0.53 |
| 52-Week Price Change | -75.47% |
| 50-Day Moving Average | 1.56 |
| 200-Day Moving Average | 3.89 |
| Relative Strength Index (RSI) | 37.63 |
| Average Volume (20 Days) | 3,976,767 |
Short Selling Information
The latest short interest is 28,119, so 1.73% of the outstanding shares have been sold short.
| Short Interest | 28,119 |
| Short Previous Month | 26,155 |
| Short % of Shares Out | 1.73% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.36 |
Income Statement
| Revenue | n/a |
| Gross Profit | -59,000 |
| Operating Income | -7.89M |
| Pretax Income | -24.60M |
| Net Income | -24.49M |
| EBITDA | -7.84M |
| EBIT | -7.89M |
| Earnings Per Share (EPS) | -$0.01 |
Balance Sheet
The company has $6.11 million in cash and $134,000 in debt, with a net cash position of $5.97 million or $0.00 per share.
| Cash & Cash Equivalents | 6.11M |
| Total Debt | 134,000 |
| Net Cash | 5.97M |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | 12.21M |
| Book Value Per Share | 0.01 |
| Working Capital | 4.81M |
Cash Flow
In the last 12 months, operating cash flow was -$7.76 million and capital expenditures -$4,000, giving a free cash flow of -$7.76 million.
| Operating Cash Flow | -7.76M |
| Capital Expenditures | -4,000 |
| Depreciation & Amortization | 46,000 |
| Net Borrowing | -250,000 |
| Free Cash Flow | -7.76M |
| FCF Per Share | -$0.00 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Purple Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -267.67% |
| Shareholder Yield | -267.67% |
| Earnings Yield | -229.92% |
| FCF Yield | -72.86% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 2, 2026. It was a reverse split with a ratio of 1:10.
| Last Split Date | Mar 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |